Core Viewpoint - The announcement highlights that the U.S. Food and Drug Administration (FDA) has accepted the clinical trial application for LAE118, a novel PI3Kα pan-mutant selective inhibitor aimed at treating patients with PIK3CA-mutated solid tumors [1] Company Summary - The company is committed to collaborating closely with regulatory authorities to complete the relevant application for LAE118 [1] - The company has a proven track record in clinical development and licensing with LAE002 (afuresertib), reinforcing its dedication to providing precision treatments for cancer patients in need of new therapeutic options [1] Industry Summary - LAE118 represents a new therapeutic approach in the oncology sector, specifically targeting PIK3CA mutations, which are prevalent in various solid tumors [1]
来凯医药-B(02105.HK)：美国食品药品监督管理局受理LAE118新药临床试验申请